Three-monthly intravitreal bevacizumab injections for neovascular age-related macular degeneration: Short-term visual acuity results

European Journal of Ophthalmology

Volumn 20, Issue 4, 2010, Pages 740-744

  Ferraz, Daniel ^a   Bressanim, Gláucio ^a   Takahashi, Beatriz ^a   Pelayes, David ^b   Takahashi, Walter ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Age related macular degeneration; Bevacizumab; Visual acuity

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; VISUAL ACUITY;

EID: 77955793002     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067211002000415     Document Type: Article

References (20)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291: 1900-1.
2. Ferrara N. Vascular endothelial growth factor: basic science clinical progress. Endocr Rev 2004; 25: 581-611. (Pubitemid 39099316)
3. Adam is AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25: 111-8.
4. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-34.
5. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81: 154-62.
6. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142: 660-8.
7. Gragoudas ES, Adam is AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
9. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
10. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-47.
11. Spandau UH, Jonas JB. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 2006; 142: 1068-70.
12. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
13. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LAS, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006; 47: 4569-78.
14. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
15. Soliman W, Lund-Andersen H, Larsen M. Resolution of subretinal hemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. Acta Ophthalmol Scand 2006; 84: 707-8.
16. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-5.
17. Niemeyer M, Hefner L, Jochmann C, Wiedemann P. Intravitreal Bevacizumab for recurring choroidal neovascularisation. Ophthalmologe 2007; 104: 158-60.
18. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina. 2006; 26: 994-8.
19. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-83.
20. Aiello LP, Brucker AJ, Chang S, etal. Evolving guidelines for intravitreous injections. Retina 2004; 24(Suppl): S3-19.